Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Inactivated Rabies Virus-Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge.

Kurup D, Fisher CR, Smith TG, Abreu-Mota T, Yang Y, Jackson FR, Gallardo-Romero N, Franka R, Bronshtein V, Schnell MJ.

J Infect Dis. 2019 Sep 26;220(9):1521-1528. doi: 10.1093/infdis/jiz332.

PMID:
31374568
2.

Erratum: Publisher Correction: Rabies-based vaccine induces potent immune responses against Nipah virus.

Keshwara R, Shiels T, Postnikova E, Kurup D, Wirblich C, Johnson RF, Schnell MJ.

NPJ Vaccines. 2019 May 13;4:18. doi: 10.1038/s41541-019-0112-x. eCollection 2019.

3.

Rabies-based vaccine induces potent immune responses against Nipah virus.

Keshwara R, Shiels T, Postnikova E, Kurup D, Wirblich C, Johnson RF, Schnell MJ.

NPJ Vaccines. 2019 Apr 15;4:15. doi: 10.1038/s41541-019-0109-5. eCollection 2019. Erratum in: NPJ Vaccines. 2019 May 13;4:18.

4.

Avoiding preventable deaths: The scourge of counterfeit rabies vaccines.

Taylor E, Banyard AC, Bourhy H, Cliquet F, Ertl H, Fehlner-Gardiner C, Horton DL, Mani RS, Müller T, Rupprecht CE, Schnell MJ, Del Rio Vilas V, Fooks AR.

Vaccine. 2019 Apr 17;37(17):2285-2287. doi: 10.1016/j.vaccine.2019.03.037. Epub 2019 Mar 25. No abstract available.

PMID:
30922698
5.

A new recombinant rabies virus expressing a green fluorescent protein: A novel and fast approach to quantify virus neutralizing antibodies.

Qin S, Volokhov D, Rodionova E, Wirblich C, Schnell MJ, Chizhikov V, Dabrazhynetskaya A.

Biologicals. 2019 May;59:56-61. doi: 10.1016/j.biologicals.2019.03.002. Epub 2019 Mar 18.

PMID:
30898479
6.

Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses.

Du Pont V, Plemper RK, Schnell MJ.

Curr Opin Virol. 2019 Apr;35:1-13. doi: 10.1016/j.coviro.2018.12.009. Epub 2019 Feb 10. Review.

PMID:
30753961
7.

New developments in rabies vaccination.

Fisher CR, Schnell MJ.

Rev Sci Tech. 2018 Aug;37(2):657-672. doi: 10.20506/rst.37.2.2831. Review.

PMID:
30747119
8.

A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model.

Keshwara R, Hagen KR, Abreu-Mota T, Papaneri AB, Liu D, Wirblich C, Johnson RF, Schnell MJ.

J Virol. 2019 Mar 5;93(6). pii: e01865-18. doi: 10.1128/JVI.01865-18. Print 2019 Mar 15.

9.

Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (Cavia porcellus).

Liu DX, Perry DL, DeWald LE, Cai Y, Hagen KR, Cooper TK, Huzella LM, Hart R, Bonilla A, Bernbaum JG, Janosko KB, Adams R, Johnson RF, Kuhn JH, Schnell MJ, Crozier I, Jahrling PB, de la Torre JC.

J Infect Dis. 2019 May 5;219(11):1818-1822. doi: 10.1093/infdis/jiy641.

PMID:
30517671
10.

Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.

Abreu-Mota T, Hagen KR, Cooper K, Jahrling PB, Tan G, Wirblich C, Johnson RF, Schnell MJ.

Nat Commun. 2018 Oct 11;9(1):4223. doi: 10.1038/s41467-018-06741-w.

11.

Retrograde axonal transport of rabies virus is unaffected by interferon treatment but blocked by emetine locally in axons.

MacGibeny MA, Koyuncu OO, Wirblich C, Schnell MJ, Enquist LW.

PLoS Pathog. 2018 Jul 20;14(7):e1007188. doi: 10.1371/journal.ppat.1007188. eCollection 2018 Jul.

12.

The spread and evolution of rabies virus: conquering new frontiers.

Fisher CR, Streicker DG, Schnell MJ.

Nat Rev Microbiol. 2018 Apr;16(4):241-255. doi: 10.1038/nrmicro.2018.11. Epub 2018 Feb 26. Review.

PMID:
29479072
13.

Ebola Virus Localization in the Macaque Reproductive Tract during Acute Ebola Virus Disease.

Perry DL, Huzella LM, Bernbaum JG, Holbrook MR, Jahrling PB, Hagen KR, Schnell MJ, Johnson RF.

Am J Pathol. 2018 Mar;188(3):550-558. doi: 10.1016/j.ajpath.2017.11.004. Epub 2018 Feb 14.

14.

Ifit2 Is a Restriction Factor in Rabies Virus Pathogenicity.

Davis BM, Fensterl V, Lawrence TM, Hudacek AW, Sen GC, Schnell MJ.

J Virol. 2017 Aug 10;91(17). pii: e00889-17. doi: 10.1128/JVI.00889-17. Print 2017 Sep 1.

15.

Progress in Ebola Virus Vaccine Development.

Schnell MJ.

J Infect Dis. 2017 Jun 15;215(12):1775-1776. doi: 10.1093/infdis/jix190. No abstract available.

PMID:
28431160
16.

The Final (Oral Ebola) Vaccine Trial on Captive Chimpanzees?

Walsh PD, Kurup D, Hasselschwert DL, Wirblich C, Goetzmann JE, Schnell MJ.

Sci Rep. 2017 Mar 9;7:43339. doi: 10.1038/srep43339.

17.

Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens.

da Fontoura Budaszewski R, Hudacek A, Sawatsky B, Krämer B, Yin X, Schnell MJ, von Messling V.

J Virol. 2017 Mar 29;91(8). pii: e02077-16. doi: 10.1128/JVI.02077-16. Print 2017 Apr 15.

18.

Keeping it in check: chronic viral infection and antiviral immunity in the brain.

Miller KD, Schnell MJ, Rall GF.

Nat Rev Neurosci. 2016 Dec;17(12):766-776. doi: 10.1038/nrn.2016.140. Epub 2016 Nov 4. Review.

19.

One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.

Wirblich C, Coleman CM, Kurup D, Abraham TS, Bernbaum JG, Jahrling PB, Hensley LE, Johnson RF, Frieman MB, Schnell MJ.

J Virol. 2017 Jan 3;91(2). pii: e02040-16. doi: 10.1128/JVI.02040-16. Print 2017 Jan 15.

20.

Toward an Effective Ebola Virus Vaccine.

Keshwara R, Johnson RF, Schnell MJ.

Annu Rev Med. 2017 Jan 14;68:371-386. doi: 10.1146/annurev-med-051215-030919. Epub 2016 Sep 28. Review.

PMID:
27686015
21.

An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.

Johnson RF, Kurup D, Hagen KR, Fisher C, Keshwara R, Papaneri A, Perry DL, Cooper K, Jahrling PB, Wang JT, Ter Meulen J, Wirblich C, Schnell MJ.

J Infect Dis. 2016 Oct 15;214(suppl 3):S342-S354. Epub 2016 Jul 24.

22.

Everything You Always Wanted to Know About Rabies Virus (But Were Afraid to Ask).

Davis BM, Rall GF, Schnell MJ.

Annu Rev Virol. 2015 Nov;2(1):451-71. doi: 10.1146/annurev-virology-100114-055157. Epub 2015 Jun 24. Review.

PMID:
26958924
23.

Rabies Virus CVS-N2c(ΔG) Strain Enhances Retrograde Synaptic Transfer and Neuronal Viability.

Reardon TR, Murray AJ, Turi GF, Wirblich C, Croce KR, Schnell MJ, Jessell TM, Losonczy A.

Neuron. 2016 Feb 17;89(4):711-24. doi: 10.1016/j.neuron.2016.01.004. Epub 2016 Jan 21.

24.

Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.

Willet M, Kurup D, Papaneri A, Wirblich C, Hooper JW, Kwilas SA, Keshwara R, Hudacek A, Beilfuss S, Rudolph G, Pommerening E, Vos A, Neubert A, Jahrling P, Blaney JE, Johnson RF, Schnell MJ.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S414-24. doi: 10.1093/infdis/jiv251. Epub 2015 Jun 10.

25.

Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics.

Pfaller CK, Cattaneo R, Schnell MJ.

Virology. 2015 May;479-480:331-44. doi: 10.1016/j.virol.2015.01.029. Epub 2015 Feb 18. Review.

26.

Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine.

Papaneri AB, Bernbaum JG, Blaney JE, Jahrling PB, Schnell MJ, Johnson RF.

Virus Res. 2015 Feb 2;197:54-8. doi: 10.1016/j.virusres.2014.11.028. Epub 2014 Dec 4.

27.

Rhabdovirus-based vaccine platforms against henipaviruses.

Kurup D, Wirblich C, Feldmann H, Marzi A, Schnell MJ.

J Virol. 2015 Jan;89(1):144-54. doi: 10.1128/JVI.02308-14. Epub 2014 Oct 15.

28.

Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses.

Han Z, Lu J, Liu Y, Davis B, Lee MS, Olson MA, Ruthel G, Freedman BD, Schnell MJ, Wrobel JE, Reitz AB, Harty RN.

J Virol. 2014 Jul;88(13):7294-306. doi: 10.1128/JVI.00591-14. Epub 2014 Apr 16.

29.

Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs.

McGettigan JP, David F, Figueiredo MD, Minke J, Mebatsion T, Schnell MJ.

Vaccine. 2014 Mar 26;32(15):1716-9. doi: 10.1016/j.vaccine.2014.01.043. Epub 2014 Feb 7.

30.

Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo.

Hudacek AW, Al-Saleem FH, Willet M, Eisemann T, Mattis JA, Simpson LL, Schnell MJ.

Mol Ther Methods Clin Dev. 2014 Oct 1;1:14046. doi: 10.1038/mtm.2014.46. eCollection 2014.

31.

Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment.

Papaneri AB, Wirblich C, Marissen WE, Schnell MJ.

Vaccine. 2013 Dec 2;31(49):5897-902. doi: 10.1016/j.vaccine.2013.09.038. Epub 2013 Oct 10.

PMID:
24120673
32.

Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses.

Lawrence TM, Wanjalla CN, Gomme EA, Wirblich C, Gatt A, Carnero E, García-Sastre A, Lyles DS, McGettigan JP, Schnell MJ.

PLoS One. 2013 Jun 26;8(6):e67123. doi: 10.1371/journal.pone.0067123. Print 2013.

33.

Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.

Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, Feldmann F, Holbrook M, Jahrling P, Feldmann H, Schnell MJ.

PLoS Pathog. 2013;9(5):e1003389. doi: 10.1371/journal.ppat.1003389. Epub 2013 May 30.

34.

Rabies virus is recognized by the NLRP3 inflammasome and activates interleukin-1β release in murine dendritic cells.

Lawrence TM, Hudacek AW, de Zoete MR, Flavell RA, Schnell MJ.

J Virol. 2013 May;87(10):5848-57. doi: 10.1128/JVI.00203-13. Epub 2013 Mar 13.

35.

Interspecies protein substitution to investigate the role of the lyssavirus glycoprotein.

Marston DA, McElhinney LM, Banyard AC, Horton DL, Núñez A, Koser ML, Schnell MJ, Fooks AR.

J Gen Virol. 2013 Feb;94(Pt 2):284-92. doi: 10.1099/vir.0.048827-0. Epub 2012 Oct 24.

36.

Immune clearance of attenuated rabies virus results in neuronal survival with altered gene expression.

Gomme EA, Wirblich C, Addya S, Rall GF, Schnell MJ.

PLoS Pathog. 2012;8(10):e1002971. doi: 10.1371/journal.ppat.1002971. Epub 2012 Oct 11.

37.

A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence.

Papaneri AB, Wirblich C, Cann JA, Cooper K, Jahrling PB, Schnell MJ, Blaney JE.

Virology. 2012 Dec 5;434(1):18-26. doi: 10.1016/j.virol.2012.07.020. Epub 2012 Aug 11.

38.

Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.

Papaneri AB, Wirblich C, Cooper K, Jahrling PB, Schnell MJ, Blaney JE.

Vaccine. 2012 Sep 21;30(43):6136-41. doi: 10.1016/j.vaccine.2012.07.073. Epub 2012 Aug 8.

39.

Targeted single-neuron infection with rabies virus for transneuronal multisynaptic tracing.

Nguyen TD, Wirblich C, Aizenman E, Schnell MJ, Strick PL, Kandler K.

J Neurosci Methods. 2012 Aug 15;209(2):367-70. doi: 10.1016/j.jneumeth.2012.06.019. Epub 2012 Jun 26.

40.

A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus.

Wanjalla CN, Goldstein EF, Wirblich C, Schnell MJ.

Virology. 2012 May 10;426(2):120-33. doi: 10.1016/j.virol.2012.01.025. Epub 2012 Feb 16.

41.

Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses.

Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, Paragas J, Schnell MJ.

J Virol. 2011 Oct;85(20):10605-16. doi: 10.1128/JVI.00558-11. Epub 2011 Aug 17.

42.

MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection.

Nunnari G, Schnell MJ.

Front Biosci (Schol Ed). 2011 Jun 1;3:1032-7.

PMID:
21622252
43.

Rabies virus as a research tool and viral vaccine vector.

Gomme EA, Wanjalla CN, Wirblich C, Schnell MJ.

Adv Virus Res. 2011;79:139-64. doi: 10.1016/B978-0-12-387040-7.00009-3. Review.

PMID:
21601047
44.

Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.

Mustafa W, Al-Saleem FH, Nasser Z, Olson RM, Mattis JA, Simpson LL, Schnell MJ.

Vaccine. 2011 Jun 20;29(28):4638-45. doi: 10.1016/j.vaccine.2011.04.045. Epub 2011 May 5.

45.

Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV.

Wirblich C, Schnell MJ.

J Virol. 2011 Jan;85(2):697-704. doi: 10.1128/JVI.01309-10. Epub 2010 Nov 10.

46.

Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.

Wanjalla CN, Faul EJ, Gomme EA, Schnell MJ.

Vaccine. 2010 Dec 10;29(1):130-40. doi: 10.1016/j.vaccine.2010.08.042. Epub 2010 Aug 20.

47.

Rabies virus infection induces type I interferon production in an IPS-1 dependent manner while dendritic cell activation relies on IFNAR signaling.

Faul EJ, Wanjalla CN, Suthar MS, Gale M, Wirblich C, Schnell MJ.

PLoS Pathog. 2010 Jul 22;6(7):e1001016. doi: 10.1371/journal.ppat.1001016.

48.

Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways.

Langley WA, Bradley KC, Li ZN, Smith ME, Schnell MJ, Steinhauer DA.

J Virol. 2010 Aug;84(16):8300-7. doi: 10.1128/JVI.00183-10. Epub 2010 May 26.

49.

Attenuation of rabies virulence: takeover by the cytoplasmic domain of its envelope protein.

Préhaud C, Wolff N, Terrien E, Lafage M, Mégret F, Babault N, Cordier F, Tan GS, Maitrepierre E, Ménager P, Chopy D, Hoos S, England P, Delepierre M, Schnell MJ, Buc H, Lafon M.

Sci Signal. 2010 Jan 19;3(105):ra5. doi: 10.1126/scisignal.2000510.

50.

Characterization of a single-cycle rabies virus-based vaccine vector.

Gomme EA, Faul EJ, Flomenberg P, McGettigan JP, Schnell MJ.

J Virol. 2010 Mar;84(6):2820-31. doi: 10.1128/JVI.01870-09. Epub 2010 Jan 6.

Supplemental Content

Loading ...
Support Center